Continuous Glucose Monitoring in the First 6 Weeks After Transplantation in Pancreas Transplant Recipients.

K. Bonner,¹ V. Dadlani,² P. Thapa,² M. Stegall,¹ Y. Kudva.²

¹Department of Surgery, Division of Transplant Surgery, Mayo Clinic, Rochester
²Department of Medicine, Division of Endocrinology, Mayo Clinic, Rochester.

Meeting: 2016 American Transplant Congress

Abstract number: A59

Keywords: Hyperglycemia, Monitoring, Pancreas, Pancreas transplantation

Session Information

Session Name: Poster Session A: Clinical Pancreas Transplantation and All Islet Cell Transplantation Topics

Session Type: Poster Session

Date: Saturday, June 11, 2016

Session Time: 5:30pm-7:30pm

Presentation Time: 5:30pm-7:30pm

Location: Halls C&D

Introduction

The maturation of Continuous glucose monitoring (CGM) technology enables accurate characterization of daily glucose control. We investigated glucose control using CGM in the first 6 weeks after pancreas transplantation (PT) in patients with type 1 diabetes(T1D).

Method

Between 2011 and 2015, 12 insulin independent T1D patients underwent CGM on post-operative days (POD) 20±7 for 3.8 ± 1.5 days. The data were analyzed using appropriate CGM measures of glucose control. Measurements include standard measures such as mean ± SD and state of the art CGM related statistics such as % time spent in various glucose ranges and indices of hypo and hyperglycemia and average daily risk range (ADRR).

Results

Table 1 shows demographic data. Glucose control is described in Table 2. Mean blood glucose (BG) was observed to be 128.1 with SD of 13.1. Number of BG readings was 864.42 ± 397.4 during this whole period with average number of readings per day 190 ± 96.9. 91.8% of readings were in range between 70 to 180mg/dl with 0.5% below 70mg/dl and 7.8% above 180mg/dl. Average daily risk range (ADRR) 15.5 ± 15.3 with Low blood glucose index (LBGI) of 0.4 ± 0.5 and High blood glucose index (HBGI) of 2.6 ± 2.4.

Total Patients	12
Age at Transplant	48.5 ± 9
Gender Female	6
Transplant SPK PAK	6 6
Race White	12
POD CGM started	20 ± 7
Duration of CGM days	3.8 ± 1.5

CGM reading	All Patients	SPK	PAK	P value
Number of readings	864±397.4	764.3±192.2	964.5±535.3	0.42
Mean readings per day	190± 96.9	182.5±20.8	197.5±31.6	0.36
Mean BG	128.1±13.1	132.1±28.8	124.1±10.8	0.54
% ≤70mg/dL	0.5±0.4	0.3±0.8	0.7±0.5	0.34
% ≥180mg/dL	7.9±11.2	10.3±14.6	5.3±6.7	0.22
% 70-180mg/dL	91.6±11.4	89.5±14.7	94±6.7	0.36
Mean HBGI	2.1±2.4	2.8±3.2	1.5±1.3	0.57
Mean LBGI	0.4±0.4	0.5±0.6	0.4±0.2	0.67
Mean ADRR	15.5±15.3	18.4±21.5	12.6±5.7	0.81

Conclusion

CGM provides a reliable method of monitoring glucose control after pancreas transplantation. We are currently acquiring more data regarding glucose control after PT. CGM outcomes represent an important objective outcome after PT that requires inclusion in prospective studies of PT.

CITATION INFORMATION: Bonner K, Dadlani V, Thapa P, Stegall M, Kudva Y. Continuous Glucose Monitoring in the First 6 Weeks After Transplantation in Pancreas Transplant Recipients. Am J Transplant. 2016;16 (suppl 3).

To cite this abstract in AMA style:

Bonner K, Dadlani V, Thapa P, Stegall M, Kudva Y. Continuous Glucose Monitoring in the First 6 Weeks After Transplantation in Pancreas Transplant Recipients. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/continuous-glucose-monitoring-in-the-first-6-weeks-after-transplantation-in-pancreas-transplant-recipients/. Accessed May 21, 2025.

« Back to 2016 American Transplant Congress